Geron (LTS:0IV3) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IV3 Geron Corp LTS:0IV3
46 GF Score
Price $1.26
GF Value $6.76
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0IV3
46GF Score
Geron Corp LTS:0IV3
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Geron (LTS:0IV3) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of $1.26 is trading 81.3% below its estimated GF Value™ of $6.76. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for LTS:0IV3:

  • Short Ratio:
  • GF Value™: $6.76 vs. price of $1.26 (81.3% below fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the LTS:0IV3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
46GF Score

Get the complete analysis for LTS:0IV3

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price
$6.76
GF Value